Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT07213973 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT07213973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07213973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2026
Completion date
March 25, 2028
Enrollment
40 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)